120 related articles for article (PubMed ID: 2954864)
1. Endometrial morphology after 6 months of continuous treatment with a new gonadotropin-releasing hormone superagonist for contraception.
Gudmundsson JA; Lundkvist O; Bergquist C; Lindgren A; Nillius SJ
Fertil Steril; 1987 Jul; 48(1):52-6. PubMed ID: 2954864
[TBL] [Abstract][Full Text] [Related]
2. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
Bergquist C; Nillius SJ; Wide L; Lindgren A
Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
[TBL] [Abstract][Full Text] [Related]
3. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
Gudmundsson JA; Nillius SJ; Bergquist C
Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
Gudmundsson JA; Nillius SJ; Bergquist C
Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
[TBL] [Abstract][Full Text] [Related]
5. Ovulation inhibition with nafarelin acetate nasal administration for six months.
Brenner PF; Shoupe D; Mishell DR
Contraception; 1985 Dec; 32(6):531-51. PubMed ID: 2936564
[TBL] [Abstract][Full Text] [Related]
6. Peptide contraception by inhibition of ovulation with intranasal GnRH superagonist: clinical and metabolic aspects.
Gudmundsson JA; Bergquist C; Nillius SJ
Prog Clin Biol Res; 1986; 225():337-51. PubMed ID: 2947248
[TBL] [Abstract][Full Text] [Related]
7. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
8. Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.
Lemay A; Jean C; Faure N
Fertil Steril; 1987 Nov; 48(5):775-82. PubMed ID: 2959569
[TBL] [Abstract][Full Text] [Related]
9. A new superagonist of GnRH for inhibition of ovulation in women.
Nillius SJ; Gudmundsson J; Bergquist C
Ups J Med Sci; 1984; 89(2):147-50. PubMed ID: 6235657
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.
Nillius SJ
J Steroid Biochem; 1985 Nov; 23(5B):849-54. PubMed ID: 2934581
[TBL] [Abstract][Full Text] [Related]
11. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent inhibition of pituitary-ovarian function during administration of a gonadotropin-releasing hormone agonistic analog (nafarelin).
Monroe SE; Blumenfeld Z; Andreyko JL; Schriock E; Henzl MR; Jaffe RB
J Clin Endocrinol Metab; 1986 Dec; 63(6):1334-41. PubMed ID: 2946710
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ovulation: comparison between the mechanism of action of steroids and GnRH analogues.
Bouchard P; Wolf JP; Hajri S
Hum Reprod; 1988 May; 3(4):503-6. PubMed ID: 3292571
[TBL] [Abstract][Full Text] [Related]
14. Control of fertility with oral medication.
Diddle AW; Watts GF; Gardner WH; Williamson PJ
West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
17. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
18. Pill-a-month as an oral contraceptive.
Hefnawi F; Hassanein M; Younis N
Egypt Popul Fam Plann Rev; 1972 Jun; 5(1):1-17. PubMed ID: 12256024
[TBL] [Abstract][Full Text] [Related]
19. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
20. Hormonal inhibition of the endometrium for resectoscopic endometrial ablation.
Brooks PG; Serden SP; Davos I
Am J Obstet Gynecol; 1991 Jun; 164(6 Pt 1):1601-6; discussion 1606-8. PubMed ID: 1904683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
